| Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (NCT02259621) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-09-01 |
| A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer (NCT02136355) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2014-09-01 |
| A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline (NCT02080078) | AHS Cancer Control Alberta | 2014-09-01 |
| Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer (NCT02274337) | Sun Yat-sen University | 2014-09-01 |
| Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer (NCT02410382) | University of Arizona | 2014-08-27 |
| A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (NCT02075840) | Hoffmann-La Roche | 2014-08-19 |
| Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer (NCT02195453) | Shandong Cancer Hospital and Institute | 2014-08-01 |
| dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact. (NCT02195336) | Karl Kölbeck | 2014-08-01 |
| Analysis of Treatment Outcome and Toxicity in Non-small Cell Lung Cancer Patients Wither-irradiated to a High Dose for Recurrent Disease (NCT01941303) | Maastricht Radiation Oncology | 2014-08-01 |
| Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer (NCT02215356) | Betta Pharmaceuticals Co., Ltd. | 2014-08-01 |
| Transcutaneous Electrical Acupoint Stimulation for Non-small Cell Lung Cancer Patients (NCT02663492) | Tongji University | 2014-08-01 |
| The Value of Surgical Mediastinal Staging in Clinical N1 Lung Cancer (NCT02222194) | Johnny Moons | 2014-08-01 |
| Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer (NCT02273336) | University of Southern California | 2014-07-22 |
| Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer (NCT02191059) | Shandong Cancer Hospital and Institute | 2014-07-01 |
| Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer (NCT02252796) | West Virginia University | 2014-07-01 |
| A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (NCT02117024) | Heat Biologics | 2014-07-01 |
| Marker Guided Breathhold Radiotherapy in NSCLC (NCT02447900) | Steen Riisgaard Mortensen | 2014-07-01 |
| Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NCT02147990) | Clovis Oncology, Inc. | 2014-06-16 |
| Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (NCT02151149) | Celgene | 2014-06-09 |
| Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer (NCT02055170) | CancerCare Manitoba | 2014-06-01 |
| Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer (NCT02093962) | ImmunoGenesis | 2014-06-01 |
| A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer (NCT02590965) | Hutchison Medipharma Limited | 2014-05-29 |
| Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors (NCT02146170) | National Cancer Institute (NCI) | 2014-05-28 |
| Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours (NCT02094261) | AstraZeneca | 2014-05-20 |
| A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NCT02125461) | AstraZeneca | 2014-05-07 |
| Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients (NCT01968941) | Ontario Clinical Oncology Group (OCOG) | 2014-05-07 |
| A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer (NCT01500824) | Pfizer | 2014-05-01 |
| Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial (NCT02002052) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2014-05-01 |
| Study of Changes of Lymphocyte Subsets in Chemotherapy Course of Patients With Non-small Cell Lung Cancer (NCT02202655) | Beijing Chao Yang Hospital | 2014-05-01 |
| Combination of Chemotherapy and Gefitinib as First-line Treatment (NCT02148380) | Baohui Han | 2014-05-01 |
| Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements (NCT02727335) | Intergroupe Francophone de Cancerologie Thoracique | 2014-05-01 |
| A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib) (NCT02133508) | Hoffmann-La Roche | 2014-04-30 |
| Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy (NCT02151604) | Oxford University Hospitals NHS Trust | 2014-04-23 |
| Third-line Treatment of Gefitinib in NSCLC Patients (NCT01933347) | Guangdong Association of Clinical Trials | 2014-04-07 |
| Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients (NCT03334071) | University Hospital Southampton NHS Foundation Trust | 2014-04-04 |
| A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT02013219) | Hoffmann-La Roche | 2014-04-03 |
| Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study (NCT01836692) | Prof Corinne Faivre-Finn | 2014-04-01 |
| Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer (NCT02132325) | Mayo Clinic | 2014-04-01 |
| A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations (NCT02109016) | Clovis Oncology, Inc. | 2014-04-01 |
| TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx) (NCT01888601) | University College, London | 2014-04-01 |
| Prognostic and Dynamic Change of CTC Enumeration in Advanced NSCLC With Chemotherapy and Targeted Therapy (NCT02155426) | Sun Yat-sen University | 2014-04-01 |
| LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (NCT02040870) | Novartis Pharmaceuticals | 2014-03-07 |
| A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer (NCT02082210) | Eli Lilly and Company | 2014-03-07 |
| Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) (NCT02134015) | Daiichi Sankyo | 2014-03-01 |
| Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib (NCT01487265) | SCRI Development Innovations, LLC | 2014-03-01 |
| Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC (NCT02367443) | Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology Centre | 2014-03-01 |
| Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients. (NCT02109549) | Maastricht Radiation Oncology | 2014-03-01 |
| Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation (NCT02095782) | Guangdong Association of Clinical Trials | 2014-03-01 |
| MK-3475 in Melanoma and NSCLC Patients With Brain Metastases (NCT02085070) | Yale University | 2014-03-01 |
| Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) (NCT02080650) | Duke University | 2014-03-01 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025) (NCT02007070) | Merck Sharp & Dohme LLC | 2014-02-28 |
| A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (NCT02087423) | AstraZeneca | 2014-02-25 |
| The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated With Concurrent Chemo/Radiotherapy (NCT01809756) | Amphia Hospital | 2014-02-25 |
| Study of the Glutaminase Inhibitor CB-839 in Solid Tumors (NCT02071862) | Calithera Biosciences, Inc | 2014-02-01 |
| Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. (NCT02012231) | Fore Biotherapeutics | 2014-02-01 |
| Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency (NCT02062515) | Betta Pharmaceuticals Co., Ltd. | 2014-02-01 |
| Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC (NCT02064491) | Finnish Lung Cancer Group | 2014-02-01 |
| Tumor-specific T Cells in Lung Cancer (NCT02515760) | University Hospital Heidelberg | 2014-02-01 |
| An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations (NCT02192697) | Astellas Pharma Inc | 2014-01-23 |
| A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT02031458) | Hoffmann-La Roche | 2014-01-22 |
| A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer (NCT02031744) | Hoffmann-La Roche | 2014-01-22 |
| Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer (NCT02031601) | Qilu Hospital of Shandong University | 2014-01-01 |
| Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN) (NCT01788332) | Lisette Nixon | 2014-01-01 |
| Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer (NCT02054052) | Haihong Yang, MD, Pricipal investigator | 2014-01-01 |
| Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation (NCT02044328) | Betta Pharmaceuticals Co., Ltd. | 2014-01-01 |
| Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (NCT02014337) | Corcept Therapeutics | 2014-01-01 |
| State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients (NCT02038413) | Maastricht Radiation Oncology | 2014-01-01 |
| High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease (NCT02027090) | Betta Pharmaceuticals Co., Ltd. | 2014-01-01 |
| Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI (NCT02066870) | Betta Pharmaceuticals Co., Ltd. | 2014-01-01 |
| Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC) (NCT02058433) | Caicun Zhou | 2014-01-01 |
| Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer (NCT02016209) | Zhejiang University | 2014-01-01 |
| Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients (NCT02040064) | Gustave Roussy, Cancer Campus, Grand Paris | 2014-01-01 |
| Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer (NCT01951586) | Amgen | 2013-12-31 |
| A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation (NCT01859026) | H. Lee Moffitt Cancer Center and Research Institute | 2013-12-30 |
| Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) (NCT01982955) | Merck KGaA, Darmstadt, Germany | 2013-12-23 |
| CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200) (NCT02043665) | Viralytics | 2013-12-18 |
| Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer (NCT01998126) | University of Utah | 2013-12-02 |
| Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation (NCT02001896) | Xinjiang Medical University | 2013-12-01 |
| Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC (NCT02005120) | Zhejiang University | 2013-12-01 |
| The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections (NCT02840227) | The Cleveland Clinic | 2013-12-01 |
| Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases (NCT02162537) | Centre Hospitalier Intercommunal Creteil | 2013-12-01 |
| Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer (NCT02507518) | Centre Henri Becquerel | 2013-12-01 |
| Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy (NCT02005458) | Xiamen Amoytop Biotech Co., Ltd. | 2013-12-01 |
| Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (NCT01999673) | Peregrine Pharmaceuticals | 2013-12-01 |
| Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC (NCT02037997) | Fudan University | 2013-12-01 |
| To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer (NCT02029209) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2013-12-01 |
| Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-) (NCT02006043) | Li Zhang | 2013-12-01 |
| Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression (NCT01998061) | Zhejiang University | 2013-12-01 |
| A Prospective Epidemiologic Study of ALK-Positive NSCLC in China (NCT02042105) | Guangdong Association of Clinical Trials | 2013-11-11 |
| Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (NCT01928576) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2013-11-06 |
| A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation (NCT01728181) | University of Utah | 2013-11-01 |
| A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (NCT02015416) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-11-01 |
| A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis (NCT02803619) | Peking Union Medical College Hospital | 2013-11-01 |
| Genomic Investigation of Unusual Responders (NCT03740503) | University Health Network, Toronto | 2013-11-01 |
| Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer (NCT01837329) | University of Rochester | 2013-11-01 |
| CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer (NCT02764606) | Hospices Civils de Lyon | 2013-11-01 |
| Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²) (NCT02448758) | Centre Oscar Lambret | 2013-11-01 |
| Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor (NCT01947868) | AstraZeneca | 2013-11-01 |
| A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (NCT02000947) | MedImmune LLC | 2013-10-25 |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer (NCT01967823) | National Cancer Institute (NCI) | 2013-10-24 |